Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

January 7, 2019
Quark Venture Inc.

Vancouver, BC – January 7, 2018 – Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases. The investment, made through their Global Health Sciences Fund (GHS) is part of the $23 million Series B … Continue reading Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

Xenon Pharmaceuticals Outlines 2019 Key Milestones

Xenon Pharmaceuticals Inc.

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s … Continue reading Xenon Pharmaceuticals Outlines 2019 Key Milestones

Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production

January 3, 2019

Agenus’ R&D Project Funded by Bill & Melinda Gates Foundation Employs PCF® Technology for Potent Vaccine Ingredient FORT WORTH, Texas, January 3, 2019 – Phyton Biotech today announced an exclusive partnership with Agenus Inc. to develop an alternative manufacturing process for QS-21 to ensure a sustainable supply of this key vaccine ingredient. Agenus received a … Continue reading Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production